Scientists find how Vitamin-A derivative kills liver cancer stem cells

          Source: Xinhua| 2018-04-24 04:14:47|Editor: yan
          Video PlayerClose

          WASHINGTON, April 23 (Xinhua) -- Japanese researchers identified the mechanism that an artificial compound derived from vitamin-A targets one class of liver cancer stem cells, preventing them from giving rise to new tumors.

          A study, published on Monday in the Proceedings of the National Academy of Sciences, provides important hints for decreasing cancer recurrence and curing patients.

          Acyclic retinoid has been found to prevent the recurrence of hepatocellular carcinoma (HCC), the most common, highly-lethal form of liver cancer, the second deadliest cancer after non-small cell lung cancer. However, scientists were not clear exactly why it worked.

          The cancer has a high rate of recurrence. Surgery and other treatments are initially effective, but the cancer often relapses.

          A research group led by Soichi Kojima of the RIKEN Center for Integrative Medical Science in Japan looked at the transcriptome of cells that had been exposed to acyclic retinoid, and found that compared to control untreated cells, they had low expression of MYCN, a gene that is often expressed in tumors and is correlated with poor prognosis.

          They repressed the expression of the gene in cancer cells, and found that the reduction in MYCN expression led functionally to slower cell-cycle progression, proliferation, and colony formation, implying that the action of the acyclic retinoid on MYCN was slowing the cancer growth.

          They found that high expression of MYCN was correlated with the expression of a number of markers that are associated with cancer stem cells.

          The "cancer stem cells," are special cells that are able to survive the onslaught of chemotherapy or other treatments, then differentiating into new cancer cells and leading to recurrence.

          "When we then looked at different subpopulations of heterogeneous cancer cells and found one specific group of EpCAM-positive cancer stem cells, where MYCN was elevated," said Kojima. "We wondered if perhaps the key to acyclic retinoid's effect was its ability to target these hepatic cancer stem cells."

          Experiments revealed that when exposed to acyclic retinoid, in a dose dependent manner, the EpCAM-positive cells were selectively depleted.

          Also, the researchers took liver biopsies of patients who had been given acyclic retinoid following liver cancer surgery, and found that in four of the six who had received a higher dosage of 600 mg/d, there were decreased levels of MYCN expression.

          They looked at data from the Cancer Genome Atlas, and found that elevated expression of MYCN correlated with dramatically poorer prognosis.

          "It is remarkable that the acyclic retinoid clearly targets a certain category of cancer stem cells, and this provides us with important hints for decreasing cancer recurrence and truly curing patients. We are waiting to see what clinical data will show us," said Kojima.

          A phase 3 clinical trial of acyclic retinoid (also called Peretinoin), is currently underway to test the drug's ability to prevent HCC recurrence.

          TOP STORIES
          EDITOR’S CHOICE
          MOST VIEWED
          EXPLORE XINHUANET
          010020070750000000000000011105521371318531
          无码人妻一区二区三区四区av_亚洲精品911在线永久观看_精品一区二区国产在线观看_日韩不卡一区二区视频在线

                  中文字幕aⅴ中文字幕天堂 在线观看91精品国产免费 | 亚洲中文字幕5g在线 | 日本一区二区三区精品无卡 | 亚洲成综合人在线播放 | 日本高清视频区一区二区三 | 亚洲精品福利中文字幕 |